From Verify.Wiki
Jump to: navigation, search

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.

QuickUpload1048 20170727120829.jpg
Type Public
Founded 1988
Headquarters New York, New York
Number of employees 51-200 employees



Top 5 Recent Tweets

March 31, 2023urotoday#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene…
March 30, 2023urotoday#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

Verification history